stockrow
Friday 6 November 2026
Export TVTX’s income statement to Excel — free account
Travere Therapeutics, Inc.
TVTX Healthcare Biotechnology
Travere Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $490.7 million, up 110.5% from fiscal 2024.
- Revenue
- +36.2%
- EPS
- −290.7%
- Free cash flow
- +6,379.8%
- Total debt
- +93.8%
Quarter to September 2026, against a year earlier
49.45
0.58
+1.19%
Follow TVTX
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
6.95 | 5.09 | 8.98 | 8.56 | |
P/FCF ratio |
0.00 | 0.00 | 366.95 | 65.82 | |
P/Operating CF |
56.18 | (67.62) | 91.45 | 56.74 | |
P/B ratio |
29.69 | 27.65 | 216.56 | 246.71 | |
Price to Tangible BV |
3,550.82 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
6.92 | 5.18 | 9.17 | 8.76 | |
EV/EBITDA |
0.00 | 208.91 | 269.67 | 0.00 | |
EV/Operating CF |
89.92 | 70.10 | 58.51 | 32.30 | |
EV/FCF |
(161.30) | (93.71) | 374.80 | 67.37 | |
Quick Ratio |
2.52 | 2.81 | 3.75 | 2.75 | |
Current Ratio |
2.74 | 3.13 | 4.05 | 3.00 | |
Net Debt/EBITDA |
0.65 | (4.05) | 13.87 | (2.09) | |
Debt/Assets |
51.51% | 56.21% | 75.41% | 71.15% | |
Debt/Equity |
2.71 | 3.16 | 24.58 | 26.72 | |
Asset Turnover |
0.82 | 0.97 | 0.87 | 0.94 | |
Operating CF/Net income |
22.23 | 1.09 | (1.67) | (1.88) | |
Capex/Depreciation |
(1.25) | (0.88) | (4.98) | (5.53) | |
Interest Coverage |
(14.14) | (16.05) | 1.85 | (31.82) | |
Research and Development Expense of Revenue |
44.62% | 44.89% | 35.55% | 81.68% | |
Selling, General and Administrative Expense of Revenue |
98.51% | 63.09% | 56.68% | 43.82% | |
Intangible Assets out of Total Assets |
0.19 | 0.20 | 0.16 | 0.19 | |
Share Based Compensation of Revenue |
8.84% | 12.69% | 12.85% | 10.44% | |
Graham Net Nets |
(0.02) | (0.02) | (0.03) | (0.03) | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(0.76%) | (0.74%) | (0.79%) | (2.20%) | |
Free Cash Flow Yield |
(0.62%) | (1.09%) | 0.27% | 1.52% | |
Revenue per Share |
1.45 | 1.38 | 1.81 | 2.37 | |
Operating CF per Share |
0.68 | (0.44) | 0.62 | 1.04 | |
Capex per Share |
(0.22) | (0.24) | (0.23) | (0.30) | |
Free Cash Flow per Share |
0.46 | (0.68) | 0.40 | 0.73 | |
Cash per Share |
3.62 | 2.88 | 5.23 | 4.99 | |
Shareholders Equity per Share |
1.29 | 1.07 | 0.26 | 0.24 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
1.29 | 1.07 | 0.26 | 0.24 | |
Free Cash Flow |
41.44 | (62.54) | 37.00 | 69.45 | |
Working Capital |
277.66 | 267.24 | 463.12 | 422.53 | |
Capital Expenditures |
(19.24) | (22.18) | (21.07) | (28.75) | |
Net Current Asset Value |
(52.80) | (63.78) | (159.70) | (192.20) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.15 | 0.17 | 0.12 | 0.13 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
53.63 | 60.84 | 59.68 | 95.26 | |
Average Payables |
24.17 | 14.14 | 13.31 | 16.75 | |
Average Inventory |
6.04 | 5.14 | 5.96 | 8.03 | |
Average Assets |
599.66 | 551.99 | 677.33 | 693.41 | |
Average Common Equity |
86.95 | 65.78 | 28.63 | 48.07 |
Columns are period end dates · fundamentals updated 6 Nov 2026